CA2006322A1 - Molecules d'adn recombinant, hotes, procedes et polypeptides ressemblant aux proteines vecteurs de somatomedine humaine - Google Patents

Molecules d'adn recombinant, hotes, procedes et polypeptides ressemblant aux proteines vecteurs de somatomedine humaine

Info

Publication number
CA2006322A1
CA2006322A1 CA2006322A CA2006322A CA2006322A1 CA 2006322 A1 CA2006322 A1 CA 2006322A1 CA 2006322 A CA2006322 A CA 2006322A CA 2006322 A CA2006322 A CA 2006322A CA 2006322 A1 CA2006322 A1 CA 2006322A1
Authority
CA
Canada
Prior art keywords
polypeptides
carrier protein
dna molecules
human
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2006322A
Other languages
English (en)
Other versions
CA2006322C (fr
Inventor
Emerald Martin Spencer
Carol Talkington-Verser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23115154&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2006322(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2006322A1 publication Critical patent/CA2006322A1/fr
Application granted granted Critical
Publication of CA2006322C publication Critical patent/CA2006322C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002006322A 1988-12-22 1989-12-21 Molecules d'adn recombinant, hotes, procedes et polypeptides ressemblant aux proteines vecteurs de somatomedine humaine Expired - Fee Related CA2006322C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29025088A 1988-12-22 1988-12-22
US290,250 1988-12-22

Publications (2)

Publication Number Publication Date
CA2006322A1 true CA2006322A1 (fr) 1990-06-22
CA2006322C CA2006322C (fr) 2000-08-01

Family

ID=23115154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002006322A Expired - Fee Related CA2006322C (fr) 1988-12-22 1989-12-21 Molecules d'adn recombinant, hotes, procedes et polypeptides ressemblant aux proteines vecteurs de somatomedine humaine

Country Status (14)

Country Link
EP (2) EP0451194B1 (fr)
JP (2) JPH04503352A (fr)
KR (1) KR910700261A (fr)
AT (1) ATE155793T1 (fr)
AU (1) AU4836890A (fr)
CA (1) CA2006322C (fr)
DE (1) DE68928203T2 (fr)
DK (1) DK95291A (fr)
ES (1) ES2107422T3 (fr)
GR (1) GR3025094T3 (fr)
HK (1) HK1000826A1 (fr)
IL (1) IL92816A0 (fr)
WO (1) WO1990006950A1 (fr)
ZA (1) ZA899832B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
EP0800530A4 (fr) * 1994-07-20 1998-12-02 Celtrix Pharma Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US20030069177A1 (en) 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
EP1141014B1 (fr) 1999-01-06 2004-12-08 Genentech, Inc. Variant mutant du facteur de croissance insulinomimetique (igf) de type i
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
CA2702192A1 (fr) 2001-03-14 2002-09-19 Genentech, Inc. Peptides antagonistes d'igf
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
PT2274978E (pt) 2003-09-12 2015-07-09 Ipsen Biopharmaceuticals Inc Métodos para tratamento da deficiência do fator de crescimento de tipo insulina i (igf-i)
CA2541015A1 (fr) 2003-10-03 2005-04-14 Genentech, Inc. Proteines de liaison a l'igf
CA2612449A1 (fr) 2005-06-17 2006-12-28 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
CN101484587B (zh) 2006-02-03 2014-02-12 英克隆有限责任公司 Igf-ir拮抗剂作为辅药用于***癌的治疗
KR20200097679A (ko) 2017-09-11 2020-08-19 샤이어 휴먼 지네틱 테라피즈 인크. 만성 폐 질환 치료를 위한 방법 및 조성물
MX2023004426A (es) 2020-10-19 2023-08-04 Oak Hill Bio Ltd Composiciones adecuadas para su uso en neonatos.
WO2023139115A1 (fr) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions et procédés pour réduire l'oxydation d'igf‐1/igfbp
WO2023242440A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Traitement des poumons chez les nourrissons
WO2023242439A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Stabilisation vasculaire (nourrissons prématurés)
WO2023242442A1 (fr) 2022-06-17 2023-12-21 Oak Hill Bio Limited Procédé de maturation/différenciation de neurones et/ou de modulation du nerf vague

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
CA1322714C (fr) * 1986-11-14 1993-10-05 Harry N. Antoniades Cicatrisation et regeneration osseuse
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
WO1989008666A1 (fr) * 1988-03-17 1989-09-21 Novo-Nordisk A/S Proteines liant l'heparine, adn codant pour ces proteines, leurs procedes de production ainsi que des preparations therapeutiques les contenant
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) * 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors

Also Published As

Publication number Publication date
GR3025094T3 (en) 1998-01-30
KR910700261A (ko) 1991-03-14
AU4836890A (en) 1990-07-10
IL92816A0 (en) 1990-09-17
WO1990006950A1 (fr) 1990-06-28
EP0375438A2 (fr) 1990-06-27
EP0375438A3 (fr) 1992-03-25
ATE155793T1 (de) 1997-08-15
ES2107422T3 (es) 1997-12-01
ZA899832B (en) 1990-10-31
EP0451194B1 (fr) 1997-07-23
DE68928203T2 (de) 1998-01-15
EP0451194A1 (fr) 1991-10-16
EP0451194A4 (en) 1992-09-02
JPH11236400A (ja) 1999-08-31
CA2006322C (fr) 2000-08-01
DK95291A (da) 1991-08-16
DK95291D0 (da) 1991-05-21
JPH04503352A (ja) 1992-06-18
HK1000826A1 (en) 1998-05-01
DE68928203D1 (de) 1997-09-04

Similar Documents

Publication Publication Date Title
CA2006322A1 (fr) Molecules d'adn recombinant, hotes, procedes et polypeptides ressemblant aux proteines vecteurs de somatomedine humaine
US5780594A (en) Biologically active protein fragments containing specific binding regions of serum albumin or related proteins
IL92257A0 (en) Binding proteins for insulin-like growth factors,pharmaceutical compositions containing them and dna fragments encoding them
WO1995021919A3 (fr) Proteine a activite de thrombopoietine (tpo)
ZA882407B (en) Human somatomedin carrier protein subunits and process for producing them
DE1003781T1 (de) Interleukin-18 bindende proteine, deren herstellung und verwendung
DE3783191D1 (de) Verfahren und mittel zur herstellung eines proteins mit der gleichen igg-spezifizitaet wie protein g.
CA2082382A1 (fr) Proteines de surface cd44 variantes, sequences d'adn codant pour ces proteines, anticorps contre ces proteines et utilisation de ces proteines a des fins diagnostiques et therapeutiques
EP0825996A4 (fr) Facteur-1 (fhf-1) homologue du facteur de croissance de fibroblastes et procedes d'utilisation
WO1995032221A3 (fr) Autotaxine: proteine stimulant la motilite, utile pour le diagnostic et la therapie du cancer
AU3346289A (en) Heparin-binding proteins, DNA coding for them, processes for producing them as well as therapeutic preparations containing them
NO177570B (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
PT98804A (pt) Processo de preparacao de igfbp-4 ou um fragmento da mesma
CA2128215A1 (fr) L'autotaxine, proteine stimulant la motilite qui est utile dans le diagnostic et le traitement du cancer
EP0261403A3 (fr) Polypeptide de rhinovirus souche HRV89, et molécule d'ADN qui l'encode
WO1995008628A3 (fr) Acides nucleiques codant la merosine, fragments de merosine et utilisations de ceux-ci
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
EP0643728A4 (fr) Proteine apparentee aux molecules d'adhesion intercellulaire.
Spencer et al. Uses for antibodies which bind to human somatomedin carrier protein subunits
IL78278A0 (en) Process for the production of polypeptides,dna sequence encoding desired polypeptide human somatomedin c polypeptide and recombinant dna molecules
MX9504057A (es) Proteina que tiene actividad tpo.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed